Viroclinics Biosciences and DDL Diagnostic Laboratory Join Forces

Rotterdam, Netherlands (ots/PRNewswire) - Two leading virology testing
laboratories integrate to form new group serving global biopharmaceutical
industry

Viroclinics Biosciences, a leading virology contract research organization,
announced today that it has acquired DDL Diagnostic Laboratory, a leading
diagnostic solutions provider. The transaction enhances the combined group's
leading global position in anti-viral and vaccine testing and will serve to
accelerate their ambitious growth strategy.

Viroclinics was founded in 2001 and specializes in the fields of virology and
global logistics services. DDL was founded in 1994 and is an expert laboratory
in advanced (molecular) diagnostic testing. Both companies operate globally,
serving leading biopharmaceutical companies active in the field of microbial
vaccines and anti-virals.

Viroclinics is the global leader in influenza and other viral targets, such as
RSV and Polio, while DDL also specializes in the fields of Hepatitis and HPV.
The combined organization will operate from four testing laboratories located in
Europe and China, with access to a global network of processing facilities
across 20 countries to coordinate sample collection in strategic regions
worldwide to serve global trials.

"By joining with DDL, we will enhance Viroclinics' leading position as a
specialized contract research organization, adding to our service offering,
capacity and geographic presence," said Bob van Gemen, Ph.D, CEO of Viroclinics
Biosciences, who will serve as CEO of the combined organization. "I look forward
to working with the DDL team and continuing to build on our leading global
position as a virology CRO."

"This is an exciting milestone for DDL. Our mission has been clear since the
start of our company: to be a premier service provider in the global pharma
services sector, with a focus on molecular diagnostics in infectious diseases,"
said Leen-Jan van Doorn, Ph.D, Chief Business Officer and co-founder of DDL. Jan
Lindeman, CEO of DDL, M.Sc. MBA, added: "The combined expertise of DDL and
Viroclinics provides an opportunity to increase our capacity, extend our service
portfolio and enhance opportunities for all employees."

The joint strengths and capabilities, and increased laboratory capacity of the
new group create a more complete portfolio of services for clients, from early
stage pre-clinical work to large scale phase 2/3 trials as well as
post-marketing studies. The combined business will employ 240 specialized
scientists, researchers, technicians and support staff.

"We believe the market opportunity is enormous," added Bob van Gemen. "Together,
the Viroclinics and DDL teams will continue to invest in virology, adjacent and
novel therapeutic fields, with the goal of serving a growing global client
base."

Financial details are not disclosed.

https://www.viroclinics.eu/press-releases/viroclinics-biosciences-and
-ddl-diagnostic-laboratory-join-forces/ (https://www.viroclinics.eu/press-releas
es/viroclinics-biosciences-and-ddl-diagnostic-laboratory-join-forces/)
https://www.viroclinics.eu/wp-content/uploads/2020/03/1.jpg
https://www.viroclinics.eu/wp-content/uploads/2020/03/2.jpg
https://www.viroclinics.eu/wp-content/uploads/2020/03/Logo-DDL.png
https://www.viroclinics.eu/wp-content/uploads/2020/03/Logo-Viroclincs
.png (https://www.viroclinics.eu/wp-content/uploads/2020/03/Logo-Viroclincs.png)

About Viroclinics Biosciences

Viroclinics Biosciences is a leading virology contract research organization,
serving the biopharmaceutical community with a broad range of preclinical,
clinical diagnostic, assay development and clinical trial logistics services.
Operating at a global level, Viroclinics is the preferred virology testing
laboratory for several of the top-10 biopharmaceutical companies. Viroclinics'
extensive experience with clinical and preclinical studies for viruses,
including its specialty in respiratory viruses, puts the company at the
forefront in supporting the development of vaccines, antibodies and antiviral
compounds targeting viral infectious diseases. Viroclinics is based in
Rotterdam, the Netherlands and employs more than 160 well-trained, dedicated
scientists and technical experts.

More information: www.viroclinics.com

About DDLDDL Diagnostic Laboratory (DDL) is a state-of-the-art laboratory
specialized in (molecular) diagnostic testing and diagnostic assay development.
DDL performs advanced (molecular) diagnostic testing on behalf of pharmaceutical
companies and clinical laboratories. DDL also designs, develops, and validates
novel diagnostic assays, which can be tailored to specific diagnostic purposes.
DDL is based in Rijswijk, the Netherlands and has a core team of 80
quality-minded employees with proven scientific and clinical laboratory
experience. DDL offers state-of-the-art diagnostic services to its customers,
and provides flexible, creative, and cost-effective advanced diagnostic
solutions. Currently, DDL serves multiple international pharmaceutical
companies, including 10 of the worldwide top-20.

More information: www.ddl.nl

Additional content: https://www.presseportal.de/pm/141941/4536589
OTS: Viroclinics Biosciences

Original-Content von: Viroclinics Biosciences, übermittelt durch news aktuell